Hormonal
Weight loss improves insulin sensitivity primarily through the reduction of visceral adipose tissue (VAT), whereas changes in total fat mass or subcutaneous abdominal fat do not significantly predict this improvement.
To improve insulin sensitivity, focus on losing visceral fat through caloric restriction. While total weight loss occurs, the specific reduction of visceral adipose tissue is the primary driver of metabolic improvement, not just the total amount of weight or subcutaneous fat lost. A moderate weight loss (e.g., 15%) is sufficient to significantly improve insulin sensitivity, primarily by targeting visceral stores.
the percent change in VAT correlated significantly with the change in insulin sensitivity... changes in insulin sensitivity did not significantly relate to the decreases measured in other regional depots of adiposity, including that of subcutaneous abdominal adipose tissue... The most straightforward explanation for these results is that visceral adipose tissue has a stronger relationship with obesity-related insulin resistance than systemic adiposity or subcutaneous abdominal adiposity.
Why this rating
Randomized controlled trial with rigorous measurement (euglycemic insulin clamp) and clear statistical correlation, though observational in nature regarding the specific fat depot correlation.
Source
Effects of weight loss on regional fat distribution and insulin sensitivity in obesity.
Bret H. Goodpaster et al. · Diabetes · 1999
DOI 10.2337/diabetes.48.4.839
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →